KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Cost of Revenue (2017 - 2025)

BeOne Medicines (ONC) has disclosed Cost of Revenue for 9 consecutive years, with $142.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 11.3% to $142.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $668.5 million, a 12.53% increase, with the full-year FY2025 number at $668.5 million, up 12.53% from a year prior.
  • Cost of Revenue was $142.4 million for Q4 2025 at BeOne Medicines, down from $196.5 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $196.5 million in Q3 2025 to a low of $32.7 million in Q1 2021.
  • A 5-year average of $104.7 million and a median of $96.1 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 153.46% in 2021, then dropped 11.3% in 2025.
  • BeOne Medicines' Cost of Revenue stood at $48.5 million in 2021, then surged by 51.45% to $73.5 million in 2022, then surged by 43.95% to $105.8 million in 2023, then surged by 51.71% to $160.6 million in 2024, then decreased by 11.3% to $142.4 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Cost of Revenue are $142.4 million (Q4 2025), $196.5 million (Q3 2025), and $164.6 million (Q2 2025).